Efpia, ‘patent revocation opens the door to counterfeit vaccines’

A patent suspension “risks diverting raw materials and supplies from well-established and effective supply chains to less efficient production sites where productivity and quality can be a problem.” This is the warning launched by EFPIA (European Federation of Pharmaceutical Industries and Associations), which comments in a note on the openings of the US and the EU on proposals that aim to revoke the protection of intellectual property on anti-Covid vaccines. It would be a decision, comments the director general of European Farmindustria, Nathalie Moll, which “opens the door to counterfeit vaccines entering the supply chain around the world”.